Thanks Thanks:  1
Likes Likes:  0
Results 1 to 1 of 1
  1. #1
    Join Date
    Aug 2005
    0 Post(s)
    0 Thread(s)

    Austedo: Medication Development for Tourette Tics

    Teva and Nuvelution Pharma Partner to Accelerate Development of AUSTEDO? (deutetrabenazine) Tablets for Use in Tourette Syndrome in the United States
    September 19, 2017

    Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) and Nuvelution Pharma, Inc. today announced their partnership to develop AUSTEDO? (deutetrabenazine) tablets for the treatment of tics associated with Tourette syndrome (TS) in pediatric patients in the United States. This partnership will accelerate development of Austedo? in TS, hopefully bringing a much needed new treatment option to affected young patients more quickly.

    About AUSTEDO
    AUSTEDO? is a vesicular monoamine transporter 2 (VMAT2) inhibitor approved by the U.S. Food and Drug Administration for the treatment of tardive dyskinesia in adults and for the treatment of chorea associated with Huntington?s disease.

    Complete article

    Related articles:

    Globes English - Teva teams with Nuvelution on Tourette syndrome drug


    Attached is PDF of U.S. Full Prescribing Information, including Boxed Warning
    Attached Files Attached Files



Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts

Disclaimer: PsychLinks is not responsible for the content of posts or comments by forum members.

Additional Forum Web Design by PsychLinks
© All rights reserved.